FDA Authorizes New Test Built With Machine Learning to Detect Past COVID-19 Infections Adaptive Biotech received FDA emergency use authorization for T-Detect™ COVID, its test for past COVID-19 infections using genetic techniques to... March 12, 2021Business, Finances, Insurance & Regulatory, C19 - Updates, COVID-19, NewsBy Brad Hedrick
FDA Approves Lisocabtagene Maraleucel (liso-cel or JCAR-017) a CAR-T Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Below is the letter we received with the details for this remarkable COVID inspired program. It contains links to a... February 6, 2021Business, Finances, Insurance & Regulatory, CAR-T, NewsBy Brad Hedrick
CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia (CLL) This was a gutsy trial, a first of its kind head-to-head comparison between two Bruton Tyrosine Kinase (BTK) inhibitors, acalabrutinib... January 29, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
COVID Patient Support Program Extension: Free Medication from Bristol Myer Squibb (BMS) Below is the letter we received with the details for this remarkable COVID inspired program. It contains links to a... January 27, 2021Business, Finances, Insurance & Regulatory, C19 - Updates, NewsBy Brad Hedrick
NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL... January 4, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients... November 25, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia Calquence (acalabrutinib) is a 2nd generation BTK inhibitor with a different side effect profile than ibrutinib. It is already approved... November 13, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
NICE okays chemotherapy-free combination venetoclax plus obinutuzumab for all front-line patients with chronic lymphocytic leukaemia (CLL) NICE gives green light for chemotherapy-free combination of venetoclax plus obinutuzumab for all front-line patients with CLL ... November 13, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
The LLS CLL Co-Pay Assistance Fund is Open! LLS may be able to help pay your insurance premiums and co-pays if you are in active treatment or are... October 30, 2020Business, Finances, Insurance & RegulatoryBy Brad Hedrick
FDA Grants Fast Track Designation to Ublituximab Plus Umbralisib in Chronic Lymphocytic Leukemia With this fast track designation, the combination of ublituximab and umbralisib should move through the FDA's approval process more quickly,... October 27, 2020Business, Finances, Insurance & RegulatoryBy Brad Hedrick
